Current Oncology (May 2024)

Oncologist-Reported Barriers and Facilitators to Offering Cancer Clinical Trials to Their Patients

  • Brenda S. Castillo,
  • Leigh Boehmer,
  • Janelle Schrag,
  • Alexandra Howson,
  • Randall Oyer,
  • Lori Pierce,
  • Nadine J. Barrett,
  • Carmen E. Guerra

DOI
https://doi.org/10.3390/curroncol31060230
Journal volume & issue
Vol. 31, no. 6
pp. 3017 – 3029

Abstract

Read online

NCCN guidelines indicate that cancer clinical trials (CCTs) are the best management for patients with cancer. However, only 5% of patients enroll in them. We examined oncologists’ perceived barriers and facilitators to discussing CCTs. This qualitative study was part of the ASCO-ACCC Initiative to Increase Racial and Ethnic Diversity in Clinical Trials. Barriers and facilitators at the system, trial, provider, and patient levels were examined. To achieve triangulation, patient encounters were reviewed using chart-stimulated recall (CSR) methods, thereby obtaining a valid assessment of physician performance. Ten oncology providers participated in this study. Nine were oncologists, and one was a clinical research coordinator; five were female; four were White; three were Asian; and three were Black. Barriers to offering CCTs were a lack of trial availability; ineligibility; a lack of knowledge; assumptions about patient interest, benefits, or harms; patient’s disease factors; and negative attitudes. Facilitators of offering CCTs were a physical space to discuss trials; greater trial availability; a systematic approach to offering trials; patient factors; patients seeking trials; a lack of comorbidities; patients being younger in age; patients being aware of, asking about, or hearing of trials from their surgeon; and higher levels of altruism. Many of the cited barriers are addressable with the cited facilitators. A larger study is needed to generalize and validate these findings.

Keywords